Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

pancreatic neoplasms/tyrosine

Länken sparas på Urklipp
9 resultat

AKT tyrosine 176 phosphorylation cancer biomarker

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status. BACKGROUND OF THE INVENTION The intracellular tyrosine

DNA damaging agents in combination with tyrosine kinase inhibitors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the field of biochemical pathways. More particularly, it concerns the pathways connecting DNA damage and phosphorylation by tyrosine kinaseses. 2. Description of the Related Art Current treatment methods

Antibodies

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2016, is named OTJ_009US_Sequence.txt and is 27,712 bytes in

Annexin A2 as immunological target

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD OF THE INVENTION This invention is related to the area of tumor immunology. In particular, it relates to highly immunogenic proteins found on tumor cells. BACKGROUND OF THE INVENTION Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignant disease with a median survival of

6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said

Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD This disclosure concerns inhibitors of the T-cell specific alternative p38 activation pathway and their use for the treatment of p38-associated diseases, such as autoimmune and inflammatory disorders, including inflammatory cancers. In particular, this disclosure concerns Gadd45.alpha.

6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said

Pyrimido compounds having antiproliferative activity

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention is directed to novel pyrimido compounds that inhibit the Src family of non-receptor tyrosine kinases (SFKs). These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer,

Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge